Live Breaking News & Updates on Fibrostenosing Crohn

Stay updated with breaking news from Fibrostenosing crohn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Agomab Therapeutics NV: Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis

Agomab Therapeutics NV: Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Tim Knotnerus , Gretchen Schweitzer , Stefan Klotter , Trophic Communications , Single Ascending Dose , Multiple Ascending Dose , Chief Development Officer , Idiopathic Pulmonary Fibrosis , Fibrostenosing Crohn , Idiopathic Pulmonary , Transforming Growth Factor , Hepatocyte Growth Factor , Agomab Therapeutics , Stephanie May , Lassen Sie ,

Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis

GHENT, Belgium, December 14, 2023 Agomab Therapeutics NV (‘Agomab’) today announced that it has dosed the first subject in a first-in-human Phase 1 clinical study of AGMB-447, an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). The study is evaluating AGMB-447 in healthy subjects and in patients with idiopathic pulmonary fibrosis (IPF). ....

Gretchen Schweitzer , Tim Knotnerus , Trophic Communications , Agomab Therapeutics , Single Ascending Dose , Multiple Ascending Dose , Chief Development Officer , Idiopathic Pulmonary Fibrosis , Fibrostenosing Crohn , Idiopathic Pulmonary , Transforming Growth Factor , Hepatocyte Growth Factor , Stephanie May , Lung Transplant , Lung Diseases , Business Wire ,

Agomab Therapeutics NV: Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline

Agomab Therapeutics NV: Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Colleen Cuffaro , Tim Knotnerus , Felice Verduyn Van Weegen , Iyona Rajkomar , Fidelity Management Research Company , Trophic Communications , Life Sciences , Dawn Biopharma , Fibrostenosing Crohn , Idiopathic Pulmonary Fibrosis , Felice Verduyn , Chief Executive Officer , Agomab Therapeutics , Stephanie May , Aktien Sie ,

Belgian biotech company Agomab Therapeutics raises €94.9M to tackle fibrosis; here's how

Ghent, Belgium-based Agomab Therapeutics, a biotech company, announced on Wednesday that it has closed a $100M (approximately €94.9M). ....

Felice Verduyn Van Weegen , Colleen Cuffaro , Iyona Rajkomar , Tim Knotnerus , Fidelity Management Research Company , Life Sciences , Belgium Based Agomab Therapeutics , Fidelity Management , Research Company , Dawn Biopharma , Fibrostenosing Crohn , Agomab Therapeutics , Idiopathic Pulmonary Fibrosis , Advancing Fibrosis Focused , Chief Executive Officer ,

Agomab Raises $100M in Series C Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time! ....

Tim Knotnerus , Fidelity Management Research Company , Life Sciences , Fidelity Management , Research Company , Dawn Biopharma , Fibrostenosing Crohn ,